why choose us

First received: September 25, 2023

Clinical Trial: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Estrogen-receptor-positive Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With

Brief Summary: Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women.Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype.Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting.The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining…

Read more